Randall Barton, PhD
Chief Scientific Officer

Expert in Receptor-based Drug Development.
Dr. Barton was most recently the Director of In-vitro Cardiovascular Researchat Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT. There he was responsible for establishing in vitro drug discovery in cardiovascular research with a partial focus on exploiting immune & inflammatory mechanisms. His work encompassed therapeutic target identification, evaluation, validation, & implementation involving molecular, biochemical & cellular research for lead optimization of both small molecules and biological drug candidates. Before this, he was Director of a group responsible for gene therapy, monoclonal antibody, and biological drug discovery involving target ID, validation & implementation. This work encompassed both in vitro and in vivo lead optimization & evaluation. Prior to this, his work in immunological and inflammatory diseases involved both small molecule and monoclonal antibody drug candidates targeting tyrosine kinases, proteases and cell surface molecules involved in leukocyte activation an migration.
Dr. Barton holds 5 US patents and has 3 patent applications in progress. He has over 60 scientific publications. He has served in the military in the Department of Gastroenterology at the Walter Reed Army Institute of Research. He holds a Ph.D. in immunology from the University of Tennessee.